[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) insider selling reported on Form 4. Executive Vice President & CFO Tasos Konidaris disposed of a total of 499,730 shares across three sale dates: 161,365 shares on 08/13/2025 at a weighted average price of $9.22, 119,206 shares on 08/14/2025 at $9.30, and 219,159 shares on 08/15/2025 at $9.43. After these transactions the reporting person beneficially owned 122,152 shares.

The filing shows the sales were executed in multiple transactions with price ranges disclosed in footnotes and signed by an attorney-in-fact. No derivative transactions, grants, or acquisitions are reported on this form and no explanatory statements beyond weighted-average price ranges were provided.

Positive

• None.

Negative

• Executive sold a large block of shares: total disposals of 499,730 shares across 08/13–08/15/2025
• Significant reduction in beneficial ownership: holdings fell to 122,152 shares after the reported sales
• No acquisition or hedging activity disclosed: Table II shows no derivative purchases or exercises to offset the disposals

Insights

Securities Analyst

TL;DR: Significant insider share sales by the CFO reduced holdings to 122,152 shares.

The Form 4 reports a block of insider sales totaling 499,730 shares over three consecutive days with weighted-average prices between $9.22 and $9.43 and disclosed price ranges per footnotes. This is a clear disclosure of disposition rather than an acquisition or option exercise. For investors, concentrated insider selling can be a signal to review company fundamentals and recent disclosures, though the filing does not state any reason for the sales or whether they follow a pre-arranged plan.

Corporate Governance Expert

TL;DR: The filing documents routine disposition activity by an executive; no governance actions or derivatives disclosed.

The report identifies the reporting person as Executive Vice President & CFO and shows direct ownership after sales of 122,152 shares. There are clear footnotes explaining weighted-average pricing ranges for each sale date, and the signature is by an attorney-in-fact. The filing lacks any indication of a 10b5-1 plan checkbox or commentary, so governance context is limited to the raw transaction disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Konidaris Tasos

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President & CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/13/2025		S		161,365	D	$9.22(1)	460,517	D
Class A Common Stock	08/14/2025		S		119,206	D	$9.3(2)	341,311	D
Class A Common Stock	08/15/2025		S		219,159	D	$9.43(3)	122,152	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

2. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.34 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

3. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AMRX CFO Tasos Konidaris report on Form 4?

He reported selling a total of 499,730 shares in three transactions on 08/13/2025 (161,365 shares at a weighted average $9.22), 08/14/2025 (119,206 shares at $9.30), and 08/15/2025 (219,159 shares at $9.43). After these sales he beneficially owned 122,152 shares.

Were any derivative transactions or option exercises reported in this Form 4 for AMRX?

No. Table II lists no derivative securities acquired, disposed of, or beneficially owned; the filing only reports non-derivative common stock sales.

Do the footnotes explain the sale prices in the AMRX Form 4?

Yes. Each footnote states the reported price is a weighted average and provides the range of execution prices for the multiple transactions on each date.

Was the Form 4 signed and by whom?

The form was signed by /s/ Denis Butkovic, Attorney-in-Fact on 08/15/2025, indicating an authorized filing on behalf of the reporting person.